Opus Genetics (IRD)
Develops mutation-specific retinal gene therapies alongside partnered and investigational ophthalmology medicines.
$5.12
After-hours close−0.03 (−0.57%)
At close$5.15(−1.34%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
estimated · in 50 days
EPS estimate
−$0.14
Revenue estimate
$1.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.27−$0.24−$0.12−$0.25−$0.14−$0.75−$0.14Pending
Estimate−$0.34−$0.34−$0.25−$0.14−$0.11−$0.16−$0.16−$0.14
Surprise−273.5%+29.4%+52.0%−78.6%−27.3%−368.7%+10.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$4.3M$4.4M$2.9M$3.1M$3.9M$2.2M$755.0KPending
Estimate$3.4M$3.1M$4.1M$3.1M$3.1M$2.9M$2.6M$1.5M
Surprise+26.5%+41.0%−28.8%+0.2%+22.9%−26.3%−71.3%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2029 | $0.61 | — | — |
| Sep 2029 | $0.55 | — | — |
| Jun 2029 | $0.47 | — | — |
| Mar 2029 | $0.41 | — | — |
| Dec 2028 | $0.30 | — | — |
| Sep 2028 | $0.27 | — | — |
| Jun 2028 | $0.23 | — | — |
| Mar 2028 | $0.20 | — | — |
| Dec 2027 | −$0.15 | — | — |
| Sep 2027 | −$0.17 | — | — |
| Jun 2027 | −$0.17 | — | — |
| Mar 2027 | −$0.16 | — | — |
| Dec 2026 | −$0.09 | — | — |
| Nov 2026 | −$0.14 | — | — |
| Aug 2026 | −$0.16 | −$0.14 | +10.6% |
| May 2026 | −$0.16 | −$0.75 | −368.7% |
| Mar 2026 | −$0.11 | −$0.14 | −27.3% |
| Nov 2025 | −$0.14 | −$0.25 | −78.6% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Dec 2022 | |||
| Nov 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2029 | $0.61 | — | — | $1.0M | — | — | — |
| Sep 2029 | $0.55 | — | — | $989.1K | — | — | — |
| Jun 2029 | $0.47 | — | — | $968.7K | — | — | — |
| Mar 2029 | $0.41 | — | — | $948.8K | — | — | — |
| Dec 2028 | $0.30 | — | — | $929.3K | — | — | — |
| Sep 2028 | $0.27 | — | — | $910.2K | — | — | — |
| Jun 2028 | $0.23 | — | — | $891.5K | — | — | — |
| Mar 2028 | $0.20 | — | — | $873.2K | — | — | — |
| Dec 2027 | −$0.15 | — | — | $5.7M | — | — | — |
| Sep 2027 | −$0.17 | — | — | $1.7M | — | — | — |
| Jun 2027 | −$0.17 | — | — | $1.7M | — | — | — |
| Mar 2027 | −$0.16 | — | — | $1.7M | — | — | — |
| Dec 2026 | −$0.09 | — | — | $6.9M | — | — | — |
| Nov 11, 2026 | −$0.14 | — | — | $1.5M | — | — | — |
| Aug 6, 2026 | −$0.16 | −$0.14 | +10.6% | $2.6M | $755.0K | −71.3% | −1.6% |
| May 12, 2026 | −$0.16 | −$0.75 | −368.7% | $2.9M | $2.2M | −26.3% | +1.2% |
| Mar 10, 2026 | −$0.11 | −$0.14 | −27.3% | $3.1M | $3.9M | +22.9% | +1.7% |
| Nov 12, 2025 | −$0.14 | −$0.25 | −78.6% | $3.1M | $3.1M | +0.2% | −2.5% |
| Aug 13, 2025 | |||||||
| May 15, 2025 | |||||||
| Mar 31, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 10, 2024 | |||||||
| Mar 8, 2024 | |||||||
| Nov 13, 2023 | |||||||
| Aug 11, 2023 | |||||||
| May 15, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Nov 4, 2022 | |||||||
| Jun 30, 2022 | |||||||
| Mar 31, 2022 | |||||||
| Dec 31, 2021 | |||||||
| Sep 30, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 |